



## **Achilles Therapeutics Announces Additional Financing Plans**

February 5, 2021

**London, UK 5 February 2021** – Achilles Therapeutics (“Achilles” or the “Company”), today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States. The timing and the terms of any such offering have not yet been determined and are subject to market conditions and other factors. There is no assurance that any such additional capital raising will be completed.

This announcement is being made pursuant to and in accordance with Rule 135 under the U.S. Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

– Ends –

### **Forward-Looking Statements**

This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

### **Further information:**

#### **Lee M. Stern – VP, IR & External Communications**

+1 (332) 373-2634

[L.stern@achillestx.com](mailto:L.stern@achillestx.com)

#### **Consilium Strategic Communications**

Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

+44 (0) 203 709 5000

[achillestx@consilium-comms.com](mailto:achillestx@consilium-comms.com)